EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care

Mattias Rudebeck iD, Ciarán Scott, Nicolas Sireau, Lakshminarayan Ranganath

JIMD Reports · 2020-05 · 53 (1) · 71-79

DOI: 10.1002/jmd2.12101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JIMD Reports, online erschienen am 07.03.2020. Verfasst von Mattias Rudebeck und 3 weiteren Autor:innen. Beteiligte Einrichtung: Swedish Orphan Biovitrum Stockholm Sweden. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Orphan Biovitrum.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alkaptonuria (AKU) is an ultrarare and multifaceted disease characterized by the absence of functional homogentisate 1,2‐dioxygenase activity, the enzyme responsible for breakdown of homogentisic acid—a tyrosine‐degradation product. The presymptomatic phase of the disease makes diagnosis difficult, with many patients unidentified or diagnosed late in life.

Objective

To date, no study has analyzed the perceived impact of different symptoms or the experiences of individuals through the patient journey in the context of AKU. This study aimed to examine patients' perceptions of AKU symptoms and their impact on quality of life as well as patients' experiences of being diagnosed and living with the disease.

Methods

Data for this study were collected using a quantitative self‐report questionnaire administered online to people with AKU.

Results

Data from 45 participants indicate that symptoms with the highest impact for patients are those related to pain and ruptures, disability and inability to perform normal routines, emotional/mental health issues, and heart complications. Findings also revealed significant delays in contact with healthcare services and time to diagnosis. Furthermore, patients reported difficulty in receiving information about AKU, treatment and care, and long‐term disease management support.

Conclusions

Time to diagnosis and care of AKU is significantly delayed. Symptoms of AKU with the highest impact on quality of life for patients are those related to pain and disability and the inability to perform normal routines. Bridging any gaps between patients with AKU and healthcare professionals through education could help improve patients' experiences with AKU through the patient journey.

Schlagwörter

Stichwörter der Autor:innen

Alkaptonuriaimpact of symptomsorphan diseasepatient experiencequality of liferare disease

Autor:innen und Institutionen

  • Swedish Orphan Biovitrum Stockholm Sweden.
  • AKU Society Cambridge UK.
  • Department of Clinical Biochemistry & Metabolic Medicine Royal Liverpool University Hospital Liverpool UK.

ORCID-Profile: Mattias Rudebeck

Förderung

  • Swedish Orphan Biovitrum

Zitieren

APA

Rudebeck, M., Scott, C., Sireau, N., & Ranganath, L. (2020). A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Reports, 53(1), 71-79. https://doi.org/10.1002/jmd2.12101

Vancouver

Rudebeck M, Scott C, Sireau N, Ranganath L. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Reports. 2020;53(1):71-79. doi:10.1002/jmd2.12101

BibTeX
@article{Rudebeck2020,
  author = {Rudebeck, Mattias and Scott, Ciarán and Sireau, Nicolas and Ranganath, Lakshminarayan},
  title = {A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care},
  journal = {JIMD Reports},
  year = {2020},
  volume = {53},
  number = {1},
  pages = {71--79},
  doi = {10.1002/jmd2.12101}
}
Kostenlos starten →